Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session

1063 - Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer: Japan Clinical Oncology Group Study (JCOG1407).

Date

09 Sep 2017

Session

Poster display session

Topics

Cytotoxic Therapy;  Pancreatic Cancer

Presenters

Akira Fukutomi

Citation

Annals of Oncology (2017) 28 (suppl_5): v209-v268. 10.1093/annonc/mdx369

Authors

A. Fukutomi1, J. Mizusawa2, H. Katayama2, T. Okusaka3, T. Ito4, N. Okano5, N. Mizuno6, M. Ikeda7, M. Ueno8, K. Shioji9, M. Ozaka10, S. Shimizu11, Y. Sakamoto3, S. Kondo3, K. Kawabe12, J. Eba2, H. Ishii13, H. Fukuda2, J. Furuse14

Author affiliations

  • 1 Divison Of Gastrointestinal Oncology, Shizuoka Cancer Center, 411-8777 - Shizuoka/JP
  • 2 Jcog Data Center/operations Office, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 3 Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital, 104-0045 - Tokyo/JP
  • 4 Graduate School Of Medical Sciences, Kyushu University, 812-8582 - FUKUOKA/JP
  • 5 Department Of Medical Oncology, Kyorin University Faculty of Medicine, 1818611 - Tokyo/JP
  • 6 Department Of Gastroenterology, Aichi Cancer Center Hospital, Nagoya/JP
  • 7 Department Of Hepatobiliary And Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa/JP
  • 8 Hepatobiliary And Pancreatic Oncology, Kanagawa Cancer Center Hospital, Yokohama/JP
  • 9 Department Of Internal Medicine, Niigata Cancer Center Hospital, Niigata/JP
  • 10 Department Of Gastroenterology, The Cancer Institute Hospital of Japanese Foundation For Cancer Research, 1358550 - Tokyo/JP
  • 11 Department Of Gastroenterology, Saitama Cancer Center, Saitama/JP
  • 12 Graduate School Of Medical Sciences, Kyushu University, Fukuoka/JP
  • 13 Clinical Research Center, National Hospital Organization Shikoku Cancer Center, 791-0280 - Matsuyama/JP
  • 14 Department Of Medical Oncology, Kyorin University Faculty of Medicine, Tokyo/JP
More

Resources

Abstract 1063

Background

Gemcitabine (GEM) is a standard treatment for locally advanced pancreatic cancer (LAPC), but the prognosis is still poor. FOLFIRINOX and GEM plus nab-paclitaxel (GnP) have recently shown superior efficacy over GEM in patients (pts) with metastatic disease, and may also benefit LAPC pts. In addition, phase II study of modified FOLFIRINOX (mFOLFIRINOX), in which dose of irinotecan was reduced and bolus 5-FU was omitted, conducted in Japan showed comparable efficacy with original regimen and tolerable toxicity. The aim of this study is to evaluate the efficacy and safety of mFOLFIRINOX and GnP to determine which is more promising regimen for LAPC. Another aim of this study is to compare the selected regimen with historical control of GEM to determine which should be a standard therapy for LAPC.

Trial design

Chemotherapy-naïve pts with LAPC, an ECOG PS of 0–1, aged 20-75, and adequate organ function are randomized to mFOLFIRINOX or GnP. In the mFOLFIRINOX arm, 85 mg/m2 of oxaliplatin, 200 mg/m2 of l-leucovorin, 150 mg/m2 of irinotecan, followed by 2,400 mg/m2 of continuous 5-FU over 46 hours are infused every 2 weeks. In the GnP arm, 125 mg/m2 of nab-paclitaxel followed by 1,000 mg/m2 of gemcitabine are infused on days 1, 8, and 15 every 4 weeks. Both treatments are continued until disease progression or unacceptable toxicity. The primary endpoint is 1-year overall survival (OS). To select the more effective regimen in 1-year OS (53% vs ≥ 63%), 106 pts are needed with a probability of at least 0.85. After selecting the more promising regimen, to judge that regimen replaces GEM as a standard chemotherapy for LAPC, 120 pts are needed to maintain 80% power under the hypothesis of 1-year OS as the expected value of 70% and threshold value of 53% with one-sided alpha of 5%. The planned total sample size is 124 pts considering for a few ineligible pts and lost to follow-up. The planned accrual period is 2.5 years, and the follow-up period is 1 year for primary analysis. Thirty-six institutions are participating in this study. This study was activated in July 2016 and 24 pts were enrolled as of Apr 30, 2017.

Clinical trial identification

UMIN000023143

Legal entity responsible for the study

Japan Clinical Oncology Group

Funding

MHLW, Japan and Japan AMED

Disclosure

A. Fukutomi: Honoraria from Taiho Pharmaceutical, Lilly Japan, Yakult Honsha and Daiichi Sankyo. Advisory Role from Yakult Honsha. Research Funding from Taiho Pharmaceutical. T. Okusaka: Honoraria from Taiho Pharmaceutical, Lilly Japan and Yakult Honsha. Advisory Role from Lilly Japan, Taiho Pharmaceutical and Daiichi Sankyo. Research Funding from Lilly, Yakult Honsha and Taiho Pharmaceutical. N. Okano: Research Funding from Taiho Pharmaceutical, Lilly Japan, Yakult and Daiichi Sankyo. N. Mizuno: Honoraria from Taiho Pharmaceutical, Lilly and Yakult Honsha. Speakers\' Bureau from Taiho Pharmaceutical. Travel Expenses from Taiho Pharmaceutical and Yakult Honsha. Research Funding from Taiho Pharmaceutical. M. Ikeda: Honoraria from Taiho Pharmaceutical, Lilly Japan and Daiichi Sankyo. Advisory Role from Lilly Japan. Research Funding from Taiho Pharmaceutical, Yakult and Lilly Japan. M. Ueno: Honoraria from Taiho Pharmaceutical, Yakult Honsha and Lilly. Research Funding from Taiho Pharmaceutical and Daiichi Sankyo. M. Ozaka: Honoraria from Taiho Pharmaceutical and Yakult Honsha. S. Shimizu, H. Fukuda: Honoraria from Taiho Pharmaceutical. S. Kondo: Research Funding from Lilly. H. Ishii: Honoraria from Yakult Honsha, Taiho Pharmaceutical and Lilly Japan. Research Funding from Taiho Pharmaceutical. J. Furuse: Honoraria and Research Funding from Taiho Pharmaceutical, Yakult, Lilly Japan and Daiichi Sankyo. Advisory Role and Speakers\' Bureau from Taiho Pharmaceutical and Yakult. Advisory Role from Lilly Japan. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.